A fresh billionaire emerges in the Russian realm.
Petey Bely, Pharmaceutical Tycoon and New Russian Billionaire, Makes Waves in Drug Production
Say hello to Petey Bely, the latest billionaire to join the exclusive club of Russian magnates who've made their fortunes in the pharmaceutical industry. Forbes announced his achievement, putting his net worth at over a billion bucks. And guess who's the main shareholder? Yup, you've got it - Petchy himself, owning about 88% of Promomed, a powerhouse pharmaceutical company based in Moscow.
Promomed, a force to be reckoned with in the Russian pharmaceutical scene, has seen significant growth, thanks to its diverse portfolio of over 350 medicines. These products cater to all major segments of the market, with its R&D center and the Biokhimik plant playing crucial roles in the development, research, and production processes.
Focusing on endocrinology and oncology medications, Promemed received 38 registration certificates in 2024, 18 of which were for cancer treatments and 4 for endocrine diseases. The company's success is evident, with a market cap of 90.45 billion rubles and a share price of 425.05 rubles, as per the Moscow Exchange.
Born in '72, Petey graduated from the Moscow State Medical and Stomatological University. In 2005, he founded Promomed, which went public on the Moscow Exchange in July 2024. The IPO was a significant milestone, demonstrating investor confidence and marking the start of a new phase for Promomed.
Other billionaire pharmaceutical titans in Russia include Victor Kharitonin and Egor Kulkov, co-owners of Ogment Investments, Alexei Repik, founder of R-pharm, Vikram Puniya, founder of Pharmsintez, and Vadim Yakunin and Eduard Netelko, owners of pharmaceutical distributors Protec and Pulse.
Promomed's growth and financial performance make it one of the most dynamic and influential pharmaceutical companies in Russia. Petey Bely's rise to billionaire status is a testament to his vision and the company's potential for continued success.
In light of his successful pharmaceutical company, Promomed, Petey Bely has been recognized as a prominent figure in the Russian business and health-and-wellness sectors, particularly medical-conditions like endocrinology and oncology. Petey's entrepreneurial prowess in finance, evident through his ownership of over 88% of Promomed, has translated to significant growth for the company in the field of science and research. This development, in turn, has propelled him to join the ranks of notable Russian billionaire pharmaceutical titans, such as Victor Kharitonin, Egor Kulkov, Alexei Repik, Vikram Puniya, Vadim Yakunin, and Eduard Netelko.
